Catalent announces new President of Clinical Supply Services

Wetteny Joseph is promoted to a new position

Catalent Pharma Solutions, a global provider of drug delivery solutions, has appointed Wetteny Joseph as its new President of Clinical Supply Services.

Joseph first joined Catalent in 2008 as Corporate Controller, and in 2012, was charged with leading the finance function for the company’s Modified Release Technologies business unit. In 2013, he was promoted to Vice President of Finance for the company’s Development and Clinical Services division, which included the Clinical Supply Services business unit.

Before joining Catalent, Joseph held senior financial positions at HD Supply. He was also Corporate Controller at Hughes Supply. In his early career, Joseph spent six years at PricewaterhouseCoopers as an auditor, and as a strategic financial advisor across a variety of industries.

You may also like

Manufacturing

Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation

Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its large-scale spray drying unit (GEA PSD-4) at its Boston (MA, US) facility
Manufacturing

Catalent expands integrated development, manufacturing and supply for modalities

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service
Manufacturing

Catalent adds cryogenic capabilities to support gene development

The facility in Shiga will include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials
Manufacturing

Catalent begins $20 million construction project

The project creates space in the original building to accommodate the installation of a new, fully automatic bottle filling line
Distribution

Catalent enters commercial supply agreement

Since 2017, Harm Reduction Therapeutics has been working on a low-cost, OTC naloxone product to act as a critical tool to help stem the loss of life
Manufacturing

Catalent and Bhami announce licensing agreement

Catalent will be authorised to collaborate with its customers to evaluate BRL’s formulation technology
Manufacturing

Catalent expands platform process for viral vectors

Processes can now benefit through increased consistency and efficiency, potentially reducing the time
Subscribe now